Cat. No. 3405
Alternative Name: apoE(133-149)
Biological ActivityApolipoprotein (ApoE) peptide fragment that functions via the low-density lipoprotein receptor-related protein (LRP). Substantially reduces the symptoms of experimental autoimmune encephalomyelitis, a model of human multiple sclerosis, and suppresses inflammation, demyelination and infiltration of cells into the spinal cord. Also acts as a non-competitive antagonist at α7 nicotinic acetylcholine receptors (IC50 = 445 nM).
(Modifications: Leu-1 = N-terminal Ac, Leu-17 = C-terminal amide)
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Gay et al (2006) Apolipoprotein E-derived peptides block α7 neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes. J.Pharmacol.Exp.Ther. 316 835. PMID: 16249370.
Li et al (2006) Apolipoprotein E-derived peptides ameliorate clinical disability and inflammatory infiltrates into the spinal cord in a murine model of multiple sclerosis. J.Pharmacol.Exp.Ther. 318 956. PMID: 16740622.
Sheng et al (2008) N-methyl-D-aspartate receptor inhibition by an apolipoprotein E-derived peptide relies on low-density lipoprotein receptor-associated protein. Neuropharmacology 55 204. PMID: 18602124.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: COG 133, supplier, apoE, peptide, fragment, α7, alpha7, a7, nAChR, antagonists, NMDA, Nicotinic, Receptors, Acetylcholine, Glutamate, N-Methyl-D-Aspartate, iGluR, Ionotropic, COG133, apoE(133149), LDL, lipoprotein, apolipoproteins